SG43314A1 - Pharmacologically active cns compounds - Google Patents

Pharmacologically active cns compounds

Info

Publication number: SG43314A1
Authority: SG; Singapore
Prior art keywords: pharmacologically active; active cns; cns compounds; compounds; pharmacologically
Prior art date: 1988-12-07

Application number

SG1996008059A

Other languages

English (en)

Inventor

Alistair Ainslie Miller

Malcolm Stuart Nobbs

Richard Martin Hyde

Michael John Leach

Original Assignee

Wellcome Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-12-07

Filing date

1989-12-06

Publication date

1997-10-17

1988-12-07 Priority claimed from GB888828620A external-priority patent/GB8828620D0/en

1989-04-14 Priority claimed from GB898908561A external-priority patent/GB8908561D0/en

1989-08-18 Priority claimed from GB8918893A external-priority patent/GB8918893D0/en

1989-12-06 Application filed by Wellcome Found filed Critical Wellcome Found

1997-10-17 Publication of SG43314A1 publication Critical patent/SG43314A1/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/56—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and doubly-bound oxygen atoms bound to the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/58—Two sulfur atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SG1996008059A 1988-12-07 1989-12-06 Pharmacologically active cns compounds SG43314A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB888828620A GB8828620D0 (en)	1988-12-07	1988-12-07	Pharmaceutically active cns compounds
GB898908561A GB8908561D0 (en)	1989-04-14	1989-04-14	Pharmaceutically active cns compounds
GB8918893A GB8918893D0 (en)	1989-08-18	1989-08-18	Pharmacologically active cns compounds

Publications (1)

Publication Number	Publication Date
SG43314A1 true SG43314A1 (en)	1997-10-17

Family

ID=27264228

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG1996008059A SG43314A1 (en)	1988-12-07	1989-12-06	Pharmacologically active cns compounds

Country Status (36)

Country	Link
US (7)	US5712276A (da)
EP (8)	EP1325916B1 (da)
JP (1)	JP2795498B2 (da)
KR (1)	KR0145308B1 (da)
CN (5)	CN1052306A (da)
AP (1)	AP164A (da)
AT (4)	ATE235906T1 (da)
AU (5)	AU669929B2 (da)
CA (2)	CA2004747C (da)
CY (1)	CY2139B1 (da)
DD (1)	DD292250A5 (da)
DE (4)	DE68929460T2 (da)
DK (2)	DK175796B1 (da)
ES (4)	ES2250967T3 (da)
FI (4)	FI895821A0 (da)
GE (1)	GEP19970891B (da)
GR (1)	GR3022031T3 (da)
HK (1)	HK1004092A1 (da)
HU (3)	HUT55764A (da)
IE (1)	IE80711B1 (da)
IL (7)	IL92558A (da)
LT (1)	LT3415B (da)
LV (1)	LV10442B (da)
MC (1)	MC2076A1 (da)
MX (1)	MX9203422A (da)
MY (1)	MY115951A (da)
NO (4)	NO178926C (da)
NZ (4)	NZ244881A (da)
OA (1)	OA09148A (da)
PH (1)	PH31658A (da)
PL (1)	PL162957B1 (da)
PT (1)	PT92502B (da)
RU (2)	RU2079493C1 (da)
SG (1)	SG43314A1 (da)
SK (2)	SK279988B6 (da)
UA (2)	UA41245C2 (da)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI895821A0 (fi) *	1988-12-07	1989-12-05	Wellcome Found	Farmaceutiskt aktiva cns foereningar.
GB9012316D0 (en) *	1990-06-01	1990-07-18	Wellcome Found	Pharmacologically active cns compounds
FR2671970B1 (fr) *	1991-01-30	1995-06-23	Wellcome Found	Comprimes dispersables dans l'eau.
US5629016A (en) *	1991-01-30	1997-05-13	Glaxo Wellcome Inc.	Water-dispersible tablets
GB9215908D0 (en) *	1992-07-27	1992-09-09	Wellcome Found	Water dispersible tablets
GB9226377D0 (en) *	1992-12-18	1993-02-10	Babbedge Rachel C	Pharmaceutical compositions
JPH08504798A (ja) *	1992-12-18	1996-05-21	ザウエルカムファウンデーションリミテッド	酵素阻害薬としての，ピリミジン，ピリジン，プテリジノンおよびインダゾール誘導体
US5698226A (en) *	1993-07-13	1997-12-16	Glaxo Wellcome Inc.	Water-dispersible tablets
US5698695A (en) *	1993-09-10	1997-12-16	E. I. Du Pont De Nemours And Company	Process for preparing 2-amino-4,6-dichloropyrimidine
GB9424766D0 (en) *	1994-12-07	1995-02-08	Wellcome Found	Pharmaceutical composition
GB9518027D0 (en) *	1995-09-05	1995-11-08	Wellcome Found	Pharmacologically active compound
US6025355A (en)	1997-05-19	2000-02-15	Cambridge Neuroscience, Inc.	Pharmaceutically active compounds and methods of use
US6242198B1 (en)	1996-07-25	2001-06-05	Cambridge Neuroscience, Inc.	Methods of treatment of eye trauma and disorders
US6756389B2 (en)	1996-08-09	2004-06-29	Cambridge Neuroscience, Inc.	Pharmaceutically active compounds and methods of use
US6110902A (en) *	1997-06-23	2000-08-29	Moehler; Hanns	Method for the inhibition of neuronal activity leading to a focal epileptic seizure by local delivery of adenosine
US6440965B1 (en)	1997-10-15	2002-08-27	Krenitsky Pharmaceuticals, Inc.	Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
IT1300056B1 (it)	1998-04-17	2000-04-05	Boehringer Ingelheim Italia	Eterocicli con anello a 6 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmaci
US6420354B1 (en)	1998-06-08	2002-07-16	Advanced Medicine, Inc.	Sodium channel drugs and uses
US6583148B1 (en)	1999-04-08	2003-06-24	Krenitsky Pharmaceuticals, Inc.	Neurotrophic substituted pyrimidines
US6479498B1 (en)	1999-06-04	2002-11-12	Theravance, Inc.	Sodium channel drugs and uses
AR029489A1 (es) *	2000-03-10	2003-07-02	Euro Celtique Sa	Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
EP1303495B1 (en) *	2000-07-24	2010-05-26	Krenitsky Pharmaceuticals, Inc.	Substituted 5-alkynyl pyrimidines having neurotrophic activity
AR037233A1 (es) *	2001-09-07	2004-11-03	Euro Celtique Sa	Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
US7465735B2 (en) *	2001-11-19	2008-12-16	Basf Aktiengesellschaft	5-Phenypyrimidines their preparation compositions comprising them and their use
GB0300783D0 (en) *	2003-01-14	2003-02-12	Btg Int Ltd	Treatment of neurodegenerative conditions
US8007826B2 (en)	2003-12-11	2011-08-30	Acorda Therapeutics, Inc.	Sustained release aminopyridine composition
US8354437B2 (en) *	2004-04-09	2013-01-15	Acorda Therapeutics, Inc.	Method of using sustained release aminopyridine compositions
CA2562315A1 (en)	2004-05-19	2005-12-01	Basf Aktiengesellschaft	2-substituted pyrimidines and their use as pesticides
CN101119969B (zh) *	2004-07-15	2014-04-09	阿尔巴尼分子研究公司	芳基和杂芳基取代的四氢异喹啉及其阻断去甲肾上腺素、多巴胺和血清素的重摄取的应用
GB0603087D0 (en) *	2006-02-15	2006-03-29	Glaxo Group Ltd	Novel use
AU2008208920A1 (en) *	2007-01-24	2008-07-31	Glaxo Group Limited	Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or R(-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an NK1
GB0800741D0 (en)	2008-01-16	2008-02-20	Univ Greenwich	Cyclic triazo and diazo sodium channel blockers
WO2009123221A1 (ja) *	2008-03-31	2009-10-08	全薬工業株式会社	細胞保護作用を有するピリミジン誘導体およびその用途
US9156812B2 (en)	2008-06-04	2015-10-13	Bristol-Myers Squibb Company	Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
CN101343253B (zh) *	2008-06-24	2011-03-16	陕西师范大学	2-氨基-4,5-二芳基嘧啶类化合物及其制备方法和药物用途
AU2010247849B2 (en)	2009-05-12	2015-11-19	Albany Molecular Research, Inc.	Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
CN102638982B (zh)	2009-05-12	2015-07-08	百时美施贵宝公司	(S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途
GB201111712D0 (en)	2011-07-08	2011-08-24	Gosforth Ct Holdings Pty Ltd	Pharmaceutical compositions
WO2013138787A1 (en) *	2012-03-16	2013-09-19	The Board Of Regents For Oklahoma State University	Highly 6-substituted -2,4-diaminopyrimidines as inhibitors of anthrax
DE102013100799A1 (de) *	2012-12-21	2014-06-26	Endress + Hauser Flowtec Ag	Umformerschaltung mit einer Stromschnittstelle sowie Meßgerät mit einer solchen Umformerschaltung
ES2716762T3 (es)	2013-02-04	2019-06-14	Janssen Pharmaceutica Nv	Moduladores de FLAP
TWI644899B (zh)	2013-02-04	2018-12-21	健生藥品公司	Ｆｌａｐ調節劑
GB2560903A (en) *	2017-03-27	2018-10-03	Azad Pharmaceutical Ingredients Ag	New synthetic path to pharmaceutically acceptable vismodegib
GB202006076D0 (en)	2020-04-24	2020-06-10	Univ Greenwich	Interleukin inhibitors
GB202006080D0 (en)	2020-04-24	2020-06-10	Univ Greenwich	Cytokine storm syndrome

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2594309A (en) *		1952-04-29		Antimalarial agents and method of
US2624731A (en) *		1953-01-06		S-phenylpyrimidkn e x derivativesx
CA741825A (en) *		1966-08-30	Stenbuck Paul	Propionitrile condensation intermediates
US2602794A (en) *		1952-07-08		Process for preparation of x-amino-s
US2576939A (en) *		1951-12-04		-diamino-s-phenyl-e-alkyl-
BE518622A (da) *
FR851237A (fr) *	1938-03-07	1940-01-05	Mayer & Schmidt Schleifmaschin	Perceuse de précision à déplacement radial du porte-outil
GB691020A (en) *	1950-02-15	1953-05-06	Wellcome Found	Improvements in or relating to pyrimidine derivatives of therapeutic value and to the manufacture thereof
GB715813A (en) *	1950-06-14	1954-09-22	Wellcome Found	Improvements in derivatives of pyrimidine
US2688019A (en) *	1951-08-25	1954-08-31	Burroughs Wellcome Co	6-aryl-2,4-diamino pyrimidines and process of preparing same
DE951991C (de) *	1952-01-30	1956-11-08	Rhone Poulenc Sa	Verfahren zur Herstellung von neuen chlorierten Derivaten des Pyrimidins
DE956306C (de) *	1952-01-30	1957-01-17	Rhone Poulenc Sa	Verfahren zur Herstellung von neuen Derivaten des Pyrimidins
GB760944A (en) *	1952-11-04	1956-11-07	Wellcome Found	Improvements in and relating to pyrimidine derivatives and their manufacture
DE1009188B (de) *	1953-05-21	1957-05-29	Rhone Poulenc Sa	Verfahren zur Herstellung von Pyrimidinderivaten
DE1303727B (de) *	1959-09-03	1976-02-05	Ausscheidung aus: 14 45 176 The Wellcome Foundation Ltd., London	Alpha-Arylidensubstituierte Propioni-Irile
US3980781A (en) *	1966-03-31	1976-09-14	Imperial Chemical Industries Limited	Fungicidal composition and method containing 2-amino-pyrimidines
DE1670854B2 (de) *	1967-04-20	1977-04-28	Bayer Ag, 5090 Leverkusen	Verfahren zur herstellung von 2,4,6- trichlorpyrimidinen
US3956327A (en) *	1969-03-06	1976-05-11	Burroughs Wellcome Co.	Method of preparing 2,4-diamino-5-benzyl pyrimidines
US4005203A (en) *	1973-03-23	1977-01-25	Burroughs Wellcome Co.	Treatment of meningeal leukemia with diamino dichlorophenyl pyrimidine
US4005204A (en) *	1973-03-23	1977-01-25	Burroughs Wellcome Co.	Treatment of neoplasms in the brain with diamino dichloroalkyl pyrimidine
US4006235A (en) *	1973-03-23	1977-02-01	Burroughs Wellcome Co.	Treating CNS lymphoma
CH591457A5 (da) *	1973-11-08	1977-09-15	Hoffmann La Roche
US3940393A (en) *	1974-06-21	1976-02-24	American Home Products Corporation	Synthesis of 2,6-diaminopyrimidines
FR2306697A1 (fr) *	1975-04-10	1976-11-05	Sogeras	Nouvelles pyrimidines utilisables comme medicaments antidiabetiques et hypocholesterolemiants
GB1582245A (en) *	1976-06-09	1981-01-07	Wellcome Found	Benzyl cyanoacetal derivatives and their conversion to pyrimidine derivatives
NZ193890A (en) *	1979-06-01	1984-07-06	Wellcome Found	3,5-diamino-6-(substituted phenyl)-1,2,4-triazines and pharmaceutical compositions
US4438267A (en) *	1980-11-11	1984-03-20	Daluge Susan M	Monoheteroring compounds and their use
DK523781A (da) *	1980-11-27	1982-05-28	Wellcome Found	Fremgangsmaade til fremstilling af benzylpyrimidiner samt mellemprodukt for disse
FR2503162A1 (fr) *	1981-04-07	1982-10-08	Pharmindustrie	Nouveaux derives de piperazino-2 pyrimidine, procedes pour leur preparation et leur utilisation comme medicaments ou comme intermediaires pour la fabrication de medicaments
FR2535718A1 (fr) *	1982-11-09	1984-05-11	Sanofi Sa	(piperazinyl-1)-2 pyrimidines, leurs sels, procede pour leur preparation et compositions pharmaceutiques en contenant
US4496549A (en) *	1983-01-17	1985-01-29	American Cyanamid Company	Treatment of malaria with antibiotics
FR2539741A1 (fr) *	1983-01-21	1984-07-27	Sanofi Sa	Composes a noyau heterocyclique diazote, leur procede de preparation et les medicaments, actifs sur le systeme nerveux central, qui en contiennent
DE3321969A1 (de) *	1983-06-18	1984-12-20	Troponwerke GmbH & Co KG, 5000 Köln	2-pyrimidinyl-1-piperazin-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE3411571A1 (de) *	1984-03-29	1985-10-10	Merck Patent Gmbh, 6100 Darmstadt	Pyrimidine
FR2567518B1 (fr) *	1984-07-11	1987-11-13	Sanofi Sa	Nouveaux composes a noyau heterocyclique azote, leur preparation et les medicaments qui en contiennent
US4725600A (en) *	1984-07-13	1988-02-16	Fujisawa Pharmaceutical Co., Ltd.	Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent
EP0799617A3 (en) *	1986-02-24	1997-11-12	Mitsui Petrochemical Industries, Ltd.	Therapeutic agent for neurological diseases
AR242678A1 (es) *	1986-03-05	1993-04-30	Gonzalez Jorge Alberto	Mejoras en instrumentos musicales de cuerda de arco.
DE3620841A1 (de) *	1986-06-21	1987-12-23	Basf Ag	4-aminopyrimidinderivate
FR2602507B1 (fr) *	1986-08-08	1989-06-09	Sanofi Pharma	Procede de preparation de diamino-2,4 benzyl-5 pyrimidines
EP0330468A3 (en) *	1988-02-23	1991-04-03	Glaxo Group Limited	Use of heterocyclic derivatives as kappa-opioid receptor agonists in the treatment of cerebral ischaemia
KR890012970A (ko) *	1988-02-23	1989-09-20	추후보충	테트라히드로 이소퀴놀린 유도체
FI895821A0 (fi) *	1988-12-07	1989-12-05	Wellcome Found	Farmaceutiskt aktiva cns foereningar.
HU206337B (en) *	1988-12-29	1992-10-28	Mitsui Petrochemical Ind	Process for producing pyrimidine derivatives and pharmaceutical compositions
FR2642758B1 (fr) *	1989-02-09	1991-05-17	Esteve Labor Dr	Derives de pyrimidine,2-(4-((alpha)-heteroaryl-(alpha) aryl-((alpha)-alkyl)-methoxy)-butyl)-1-piperazinyl), avec activite serotoninergique
US5136080A (en) *	1989-12-04	1992-08-04	Burroughs Wellcome Co.	Nitrile compounds
GB9012316D0 (en) *	1990-06-01	1990-07-18	Wellcome Found	Pharmacologically active cns compounds
JPH06501926A (ja) *	1990-08-06	1994-03-03	藤沢薬品工業株式会社	複素環式化合物

1989
- 1989-12-05 FI FI895821A patent/FI895821A0/fi not_active IP Right Cessation
- 1989-12-06 AT AT95120491T patent/ATE235906T1/de not_active IP Right Cessation
- 1989-12-06 EP EP03005787A patent/EP1325916B1/en not_active Expired - Lifetime
- 1989-12-06 PT PT92502A patent/PT92502B/pt not_active IP Right Cessation
- 1989-12-06 NZ NZ244881A patent/NZ244881A/en unknown
- 1989-12-06 JP JP1317401A patent/JP2795498B2/ja not_active Expired - Fee Related
- 1989-12-06 RU SU894742852A patent/RU2079493C1/ru active
- 1989-12-06 HU HU896444A patent/HUT55764A/hu unknown
- 1989-12-06 ES ES95120378T patent/ES2250967T3/es not_active Expired - Lifetime
- 1989-12-06 EP EP95120379A patent/EP0727214A3/en not_active Withdrawn
- 1989-12-06 EP EP89312723A patent/EP0372934B1/en not_active Expired - Lifetime
- 1989-12-06 OA OA59692A patent/OA09148A/xx unknown
- 1989-12-06 EP EP95120378A patent/EP0727213B9/en not_active Expired - Lifetime
- 1989-12-06 DE DE68929460T patent/DE68929460T2/de not_active Expired - Lifetime
- 1989-12-06 EP EP95120491A patent/EP0715851B1/en not_active Expired - Lifetime
- 1989-12-06 ES ES03005787T patent/ES2300513T3/es not_active Expired - Lifetime
- 1989-12-06 PL PL28263989A patent/PL162957B1/pl not_active IP Right Cessation
- 1989-12-06 AP APAP/P/1989/000155A patent/AP164A/en active
- 1989-12-06 CA CA002004747A patent/CA2004747C/en not_active Expired - Fee Related
- 1989-12-06 ES ES89312723T patent/ES2095842T3/es not_active Expired - Lifetime
- 1989-12-06 RU RU95116245A patent/RU2121998C1/ru not_active IP Right Cessation
- 1989-12-06 EP EP95120377A patent/EP0727212A3/en not_active Withdrawn
- 1989-12-06 DE DE68929554T patent/DE68929554T2/de not_active Expired - Lifetime
- 1989-12-06 NZ NZ260820A patent/NZ260820A/en unknown
- 1989-12-06 AT AT89312723T patent/ATE144422T1/de not_active IP Right Cessation
- 1989-12-06 EP EP95120380A patent/EP0713703A3/en not_active Withdrawn
- 1989-12-06 IL IL9255889A patent/IL92558A/en not_active IP Right Cessation
- 1989-12-06 AT AT03005787T patent/ATE384703T1/de not_active IP Right Cessation
- 1989-12-06 MC MC892083A patent/MC2076A1/xx unknown
- 1989-12-06 CA CA002271566A patent/CA2271566C/en not_active Expired - Fee Related
- 1989-12-06 IE IE389489A patent/IE80711B1/en not_active IP Right Cessation
- 1989-12-06 DK DK198906132A patent/DK175796B1/da not_active IP Right Cessation
- 1989-12-06 CN CN89109759A patent/CN1052306A/zh active Pending
- 1989-12-06 UA UA4742852A patent/UA41245C2/uk unknown
- 1989-12-06 IL IL11433589A patent/IL114335A/xx active IP Right Grant
- 1989-12-06 DE DE68927368T patent/DE68927368T2/de not_active Expired - Lifetime
- 1989-12-06 DD DD89335316A patent/DD292250A5/de unknown
- 1989-12-06 NO NO894887A patent/NO178926C/no not_active IP Right Cessation
- 1989-12-06 IL IL111627A patent/IL111627A/xx not_active IP Right Cessation
- 1989-12-06 KR KR1019890018094A patent/KR0145308B1/ko not_active IP Right Cessation
- 1989-12-06 DE DE68929540T patent/DE68929540T2/de not_active Expired - Lifetime
- 1989-12-06 AT AT95120378T patent/ATE307585T1/de not_active IP Right Cessation
- 1989-12-06 MY MYPI95000966A patent/MY115951A/en unknown
- 1989-12-06 EP EP05023080A patent/EP1681058A3/en not_active Withdrawn
- 1989-12-06 ES ES95120491T patent/ES2194884T3/es not_active Expired - Lifetime
- 1989-12-06 NZ NZ244880A patent/NZ244880A/xx unknown
- 1989-12-06 SK SK6898-89A patent/SK279988B6/sk unknown
- 1989-12-06 NZ NZ231650A patent/NZ231650A/en unknown
- 1989-12-06 SG SG1996008059A patent/SG43314A1/en unknown
1992
- 1992-06-25 MX MX9203422A patent/MX9203422A/es not_active Application Discontinuation
- 1992-12-18 LV LVP-92-337A patent/LV10442B/en unknown
- 1992-12-30 LT LTIP269A patent/LT3415B/lt not_active IP Right Cessation
1993
- 1993-09-09 GE GEAP19931548A patent/GEP19970891B/en unknown
- 1993-10-20 AU AU49154/93A patent/AU669929B2/en not_active Ceased
1994
- 1994-04-05 NO NO941211A patent/NO941211D0/no unknown
1995
- 1995-05-17 PH PH50547A patent/PH31658A/en unknown
- 1995-05-23 IL IL11381895A patent/IL113818A0/xx unknown
- 1995-06-06 US US08/466,148 patent/US5712276A/en not_active Expired - Fee Related
- 1995-06-06 US US08/466,147 patent/US5684005A/en not_active Expired - Fee Related
- 1995-06-06 IL IL11401995A patent/IL114019A0/xx unknown
- 1995-06-06 US US08/470,951 patent/US5597828A/en not_active Expired - Lifetime
- 1995-06-06 US US08/470,948 patent/US5591746A/en not_active Expired - Lifetime
- 1995-06-06 US US08/466,146 patent/US5597827A/en not_active Expired - Lifetime
- 1995-06-06 US US08/469,518 patent/US5587380A/en not_active Expired - Lifetime
- 1995-06-06 US US08/466,138 patent/US5635507A/en not_active Expired - Lifetime
- 1995-06-07 IL IL11404095A patent/IL114040A0/xx unknown
- 1995-06-10 CN CN95106811A patent/CN1066720C/zh not_active Expired - Fee Related
- 1995-06-10 CN CN95105625A patent/CN1119099A/zh active Pending
- 1995-06-10 CN CN95105850A patent/CN1066719C/zh not_active Expired - Fee Related
- 1995-06-10 CN CN95106817A patent/CN1117046A/zh active Pending
- 1995-06-26 IL IL11433595A patent/IL114335A0/xx unknown
- 1995-07-03 HU HU95P/P00740P patent/HU211677A9/hu unknown
- 1995-07-03 HU HU95P/P00754P patent/HU211974A9/hu unknown
- 1995-11-08 NO NO953847A patent/NO304649B1/no not_active IP Right Cessation
- 1995-11-08 NO NO954489A patent/NO954489D0/no unknown
- 1995-12-11 FI FI955941A patent/FI955941A0/fi not_active Application Discontinuation
- 1995-12-11 FI FI955940A patent/FI955940A0/fi unknown
- 1995-12-11 FI FI955939A patent/FI955939A/fi unknown
1996
- 1996-04-24 AU AU51953/96A patent/AU5195396A/en not_active Abandoned
- 1996-04-24 AU AU51952/96A patent/AU5195296A/en not_active Abandoned
- 1996-04-24 AU AU51955/96A patent/AU690443B2/en not_active Ceased
- 1996-04-24 AU AU51956/96A patent/AU5195696A/en not_active Abandoned
- 1996-12-13 GR GR960403456T patent/GR3022031T3/el unknown
1998
- 1998-03-11 SK SK321-98A patent/SK279977B6/sk unknown
- 1998-04-20 HK HK98103302A patent/HK1004092A1/xx not_active IP Right Cessation
1999
- 1999-06-24 DK DK199900903A patent/DK175781B1/da not_active IP Right Cessation
- 1999-10-12 CY CY9900034A patent/CY2139B1/xx unknown
- 1999-11-04 UA UA99116068A patent/UA42885C2/uk unknown

Also Published As

Publication number	Publication date
CN1066720C (zh)	2001-06-06
FI955939A0 (fi)	1995-12-11
EP0713703A3 (en)	1997-10-01
US5587380A (en)	1996-12-24
PL162957B1 (pl)	1994-01-31
ES2095842T3 (es)	1997-03-01
HU211974A9 (en)	1996-01-29
EP0713703A2 (en)	1996-05-29
AU5195596A (en)	1996-07-04
UA42885C2 (uk)	2001-11-15
US5635507A (en)	1997-06-03
NO941211D0 (no)	1994-04-05
EP1325916A1 (en)	2003-07-09
EP0715851B1 (en)	2003-04-02
NO178926B (no)	1996-03-25
ES2300513T3 (es)	2008-06-16
NZ244880A (en)	1996-03-26
FI955941A (fi)	1995-12-11
EP1681058A2 (en)	2006-07-19
RU2079493C1 (ru)	1997-05-20
ATE144422T1 (de)	1996-11-15
NO894887L (no)	1990-06-08
IL111627A (en)	1997-06-10
NZ260820A (en)	1996-04-26
FI955941A0 (fi)	1995-12-11
HUT55764A (en)	1991-06-28
EP0372934A2 (en)	1990-06-13
SK32198A3 (en)	1999-06-11
LV10442A (lv)	1995-02-20
CA2271566A1 (en)	1990-06-07
IL111627A0 (en)	1995-01-24
FI895821A0 (fi)	1989-12-05
IL114335A0 (en)	1995-10-31
EP1325916B1 (en)	2008-01-23
DE68929540D1 (de)	2005-12-01
CY2139B1 (en)	2002-06-21
EP0727213B9 (en)	2007-11-07
LTIP269A (en)	1994-10-25
US5684005A (en)	1997-11-04
EP0727213B1 (en)	2005-10-26
HU211677A9 (en)	1995-12-28
IE893894L (en)	1990-06-07
IL114019A0 (en)	1995-10-31
HU896444D0 (en)	1990-02-28
AU5195396A (en)	1996-07-04
EP0715851A3 (en)	1997-10-01
AU669929B2 (en)	1996-06-27
NO941211L (no)	1990-06-08
NO178926C (no)	1996-07-03
SK689889A3 (en)	1999-06-11
DD292250A5 (de)	1991-07-25
DE68927368D1 (de)	1996-11-28
EP0715851A2 (en)	1996-06-12
NZ231650A (en)	1996-03-26
JPH02202876A (ja)	1990-08-10
AP8900155A0 (en)	1990-01-31
DK175781B1 (da)	2005-02-21
EP0727213A3 (en)	1997-09-10
AU5195696A (en)	1996-07-04
DK175796B1 (da)	2005-02-21
NO894887D0 (no)	1989-12-06
NO954490L (no)	1990-06-08
AU4915493A (en)	1994-01-13
KR900009610A (ko)	1990-07-05
IE80711B1 (en)	1998-12-16
CN1066719C (zh)	2001-06-06
DK613289A (da)	1990-06-08
DK199900903A (da)	1999-06-24
KR0145308B1 (ko)	1998-07-15
FI955939A (fi)	1995-12-11
GEP19970891B (en)	1997-11-27
LT3415B (en)	1995-09-25
FI955940A (fi)	1995-12-11
US5597827A (en)	1997-01-28
EP0727214A3 (en)	1997-10-01
PH31658A (en)	1999-01-12
NO954490D0 (no)	1995-11-08
ATE307585T1 (de)	2005-11-15
DE68929540T2 (de)	2006-06-14
US5591746A (en)	1997-01-07
IL114040A0 (en)	1995-10-31
EP0372934B1 (en)	1996-10-23
CN1119099A (zh)	1996-03-27
AU690443B2 (en)	1998-04-23
ES2250967T3 (es)	2006-04-16
EP0727214A2 (en)	1996-08-21
NO304649B1 (no)	1999-01-25
CN1113487A (zh)	1995-12-20
LV10442B (en)	1995-08-20
RU2121998C1 (ru)	1998-11-20
ES2194884T3 (es)	2003-12-01
OA09148A (en)	1991-10-31
DK613289D0 (da)	1989-12-06
US5597828A (en)	1997-01-28
EP0727212A2 (en)	1996-08-21
EP1681058A3 (en)	2008-04-16
EP0727212A3 (en)	1997-10-01
CN1115756A (zh)	1996-01-31
ATE235906T1 (de)	2003-04-15
SK279977B6 (sk)	1999-06-11
UA41245C2 (uk)	2001-09-17
PT92502B (pt)	1995-08-09
GR3022031T3 (en)	1997-03-31
PT92502A (pt)	1990-06-29
AP164A (en)	1992-01-12
NO954489D0 (no)	1995-11-08
DE68929460T2 (de)	2003-12-24
CN1117046A (zh)	1996-02-21
CA2004747C (en)	2000-05-30
NO954489L (no)	1990-06-08
HK1004092A1 (en)	1998-11-13
DE68929554D1 (de)	2008-03-13
IL92558A (en)	1996-01-31
IL114335A (en)	2000-12-06
US5712276A (en)	1998-01-27
MX9203422A (es)	1992-07-01
DE68927368T2 (de)	1997-03-13
EP0372934A3 (en)	1992-07-15
CA2004747A1 (en)	1990-06-07
FI955940A0 (fi)	1995-12-11
IL92558A0 (en)	1990-08-31
DE68929554T2 (de)	2009-01-29
CA2271566C (en)	2003-02-04
ATE384703T1 (de)	2008-02-15
MC2076A1 (fr)	1990-10-12
DE68929460D1 (de)	2003-05-08
SK279988B6 (sk)	1999-06-11
AU5195296A (en)	1996-07-18
MY115951A (en)	2003-10-31
JP2795498B2 (ja)	1998-09-10
IL113818A0 (en)	1995-08-31
NZ244881A (en)	1996-03-26
AU4596489A (en)	1990-06-14
AU639216B2 (en)	1993-07-22
CN1052306A (zh)	1991-06-19
EP0727213A2 (en)	1996-08-21

Publication	Publication Date	Title
CY2139B1 (en)	2002-06-21	Pharmacologically active CNS compounds
GB8403540D0 (en)	1984-03-14	Pharmacologically active compounds
GB8712437D0 (en)	1987-07-01	Pharmacologically active compounds
ZA914166B (en)	1993-02-24	Pharmacologically active cns compounds
GB9012312D0 (en)	1990-07-18	Pharmacologically active cns compounds
GB8622090D0 (en)	1986-10-22	Pharmacologically active compounds
GB8918893D0 (en)	1989-09-27	Pharmacologically active cns compounds
GB8616741D0 (en)	1986-08-13	Pharmacologically active compounds
HRP940540A2 (en)	1996-08-31	Pharmacologically active cns compounds
ZA899327B (en)	1991-11-27	Pharmaceutically active cns compounds
GB9218797D0 (en)	1992-10-21	Pharmacologically active compounds
AU639216C (en)	1996-12-19	Pharmaceutically active CNS compounds
GB8805811D0 (en)	1988-04-13	Pharmaceutically active compounds
GB9019593D0 (en)	1990-10-24	Novel pharmacologically active compounds
GB8625650D0 (en)	1986-11-26	Pharmacologically active compounds
GB8625649D0 (en)	1986-11-26	Pharmacologically active compounds
ZA834B (en)	1983-10-26	Pharmacologically active compounds
GB9216170D0 (en)	1992-09-09	Pharmacologically active compounds
GB9217426D0 (en)	1992-09-30	Pharmacologically active compounds
GB9220543D0 (en)	1992-11-11	Pharmacologically active compounds
GB9225497D0 (en)	1993-01-27	Pharmacologically active compounds
GB9225498D0 (en)	1993-01-27	Pharmacologically active compounds
GB8730191D0 (en)	1988-02-03	Pharmacologically active compounds & use
GB8730192D0 (en)	1988-02-03	Pharmacologically active compounds & use